This trend mirrors broader prescribing patterns nationwide, where GLP-1 receptor agonists have seen expanded use not only for glycemic control in type 2 diabetes mellitus but also increasingly for weight management in obese and overweight populations. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.